Fig. 2
From: Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
In vitro toxicity assays of HX009. (A) HX009 binding to RBC in vitro as measured by flow cytometry, with or without PNGase-F pretreatment, with Magrolimab positive being experimental control, MFI: mean fluorescence intensity; (B) HX009 binding to platelets as assayed by flow cytometry; (C) Binding to FcγRIIIa (CD16a) via ELISA method, where a human IgG1 antibody was used as positive control; (D) In vitro cytokine release from PBMC induced by HX009 with solid phase or liquid phase. Cytokines including IL-2, IL-4, IL-6, IL-10, IL-17α, TNF-α and IFN-γ were investigated by CBA flow cytometry.
